Cover Image
市場調查報告書

乾癬 : 開發平台分析

Psoriasis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232784
出版日期 內容資訊 英文 673 Pages
訂單完成後即時交付
價格
Back to Top
乾癬 : 開發平台分析 Psoriasis - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 673 Pages
簡介

所謂乾癬是指影響皮膚的慢性自體免疫性疾病,是由於細胞乾燥產生斑塊並引起發炎。症狀有以細胞脫落為首的皮膚腫、發癢、產生燒灼感。相關的危險因子有遺傳、特定藥劑的副作用、壓力、傳染病、環境狀況等。除此之外尚有免疫系統機能異常造成乾癬惡化。可用局部或全身用藥、光線治療等來控制症狀。

本報告提供乾癬的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 乾癬 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9730IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H2 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 19, 1, 20, 44, 44, 2, 106, 30 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Psoriasis - Overview
  • Psoriasis - Therapeutics Development
  • Psoriasis - Therapeutics Assessment
  • Psoriasis - Companies Involved in Therapeutics Development
  • Psoriasis - Drug Profiles
  • Psoriasis - Dormant Projects
  • Psoriasis - Discontinued Products
  • Psoriasis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Psoriasis, H2 2017 38
  • Number of Products under Development by Companies, H2 2017 40
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 41
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 42
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 43
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 44
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 45
  • Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 46
  • Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 47
  • Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 48
  • Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 49
  • Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 50
  • Number of Products under Development by Universities/Institutes, H2 2017 51
  • Products under Development by Companies, H2 2017 52
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017 53
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017 54
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017 55
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017 56
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017 57
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017 58
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017 59
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017 60
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017 61
  • Products under Development by Companies, H2 2017 (Contd..10), H2 2017 62
  • Products under Development by Companies, H2 2017 (Contd..11), H2 2017 63
  • Products under Development by Companies, H2 2017 (Contd..12), H2 2017 65
  • Products under Development by Companies, H2 2017 (Contd..13), H2 2017 66
  • Products under Development by Companies, H2 2017 (Contd..14), H2 2017 67
  • Products under Development by Universities/Institutes, H2 2017 68
  • Number of Products by Stage and Target, H2 2017 70
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 71
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 72
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 73
  • Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 74
  • Number of Products by Stage and Mechanism of Action, H2 2017 76
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 77
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 78
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 79
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 80
  • Number of Products by Stage and Route of Administration, H2 2017 82
  • Number of Products by Stage and Molecule Type, H2 2017 84
  • Psoriasis - Pipeline by 3SBio Inc, H2 2017 85
  • Psoriasis - Pipeline by AbbVie Inc, H2 2017 86
  • Psoriasis - Pipeline by Abeome Corp, H2 2017 86
  • Psoriasis - Pipeline by AbGenomics International Inc, H2 2017 86
  • Psoriasis - Pipeline by Adello Biologics LLC, H2 2017 87
  • Psoriasis - Pipeline by Affibody AB, H2 2017 87
  • Psoriasis - Pipeline by Albireo Pharma Inc, H2 2017 88
  • Psoriasis - Pipeline by Alfacyte Ltd, H2 2017 88
  • Psoriasis - Pipeline by Allergan Plc, H2 2017 88
  • Psoriasis - Pipeline by Almirall SA, H2 2017 89
  • Psoriasis - Pipeline by Alteogen Inc, H2 2017 89
  • Psoriasis - Pipeline by Amgen Inc, H2 2017 90
  • Psoriasis - Pipeline by AnaptysBio Inc, H2 2017 90
  • Psoriasis - Pipeline by ApoPharma Inc, H2 2017 91
  • Psoriasis - Pipeline by Arbor Pharmaceuticals LLC, H2 2017 91
  • Psoriasis - Pipeline by Arrien Pharmaceuticals LLC, H2 2017 91
  • Psoriasis - Pipeline by AstraZeneca Plc, H2 2017 92
  • Psoriasis - Pipeline by Athenex Inc, H2 2017 92
  • Psoriasis - Pipeline by Atlantic Bio Sci LLC, H2 2017 93
  • Psoriasis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 93
  • Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2017 94
  • Psoriasis - Pipeline by Baliopharm AG, H2 2017 94
  • Psoriasis - Pipeline by Bayer AG, H2 2017 94
  • Psoriasis - Pipeline by Beta Pharma Inc, H2 2017 95
  • Psoriasis - Pipeline by BioApex sro, H2 2017 95
  • Psoriasis - Pipeline by Biocad, H2 2017 96
  • Psoriasis - Pipeline by Biocon Ltd, H2 2017 96
  • Psoriasis - Pipeline by BioLingus AG, H2 2017 97
  • Psoriasis - Pipeline by Bionomics Ltd, H2 2017 97
  • Psoriasis - Pipeline by Bionovis SA, H2 2017 97
  • Psoriasis - Pipeline by BirchBioMed Inc, H2 2017 98
  • Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2017 98
  • Psoriasis - Pipeline by Brickell Biotech Inc, H2 2017 99
  • Psoriasis - Pipeline by Bristol-Myers Squibb Company, H2 2017 99
  • Psoriasis - Pipeline by C4X Discovery Holdings PLC, H2 2017 100
  • Psoriasis - Pipeline by CalciMedica Inc, H2 2017 100
  • Psoriasis - Pipeline by Can-Fite BioPharma Ltd, H2 2017 100
  • Psoriasis - Pipeline by Celgene Corp, H2 2017 101
  • Psoriasis - Pipeline by ChemoCentryx Inc, H2 2017 101
  • Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H2 2017 102
  • Psoriasis - Pipeline by ChironWells GmbH, H2 2017 102
  • Psoriasis - Pipeline by Coherus BioSciences Inc, H2 2017 103
  • Psoriasis - Pipeline by Compugen Ltd, H2 2017 103
  • Psoriasis - Pipeline by Concenter BioPharma Silkim Ltd, H2 2017 103
  • Psoriasis - Pipeline by conoGenetix biosciences GmbH, H2 2017 104
  • Psoriasis - Pipeline by Crescita Therapeutics Inc, H2 2017 104
  • Psoriasis - Pipeline by Dermala Inc, H2 2017 105
  • Psoriasis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H2 2017 105
  • Psoriasis - Pipeline by DURECT Corp, H2 2017 106
  • Psoriasis - Pipeline by EA Pharma Co Ltd, H2 2017 106
  • Psoriasis - Pipeline by Eli Lilly and Company, H2 2017 106
  • Psoriasis - Pipeline by ELORAC Inc, H2 2017 107
  • Psoriasis - Pipeline by Exicure Inc, H2 2017 107
  • Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 108
  • Psoriasis - Pipeline by Formycon AG, H2 2017 108
  • Psoriasis - Pipeline by Forward Pharma AS, H2 2017 109
  • Psoriasis - Pipeline by Fresenius SE & Co KGaA, H2 2017 109
  • Psoriasis - Pipeline by Galapagos NV, H2 2017 110
  • Psoriasis - Pipeline by Galderma SA, H2 2017 110
  • Psoriasis - Pipeline by Galectin Therapeutics Inc, H2 2017 110
  • Psoriasis - Pipeline by Gem Pharmaceuticals LLC, H2 2017 111
  • Psoriasis - Pipeline by Genentech Inc, H2 2017 111
  • Psoriasis - Pipeline by Genfit SA, H2 2017 112
  • Psoriasis - Pipeline by Genor BioPharma Co Ltd, H2 2017 112
  • Psoriasis - Pipeline by GlaxoSmithKline Plc, H2 2017 113
  • Psoriasis - Pipeline by GlycoMar Ltd, H2 2017 113
  • Psoriasis - Pipeline by Grupo Ferrer Internacional SA, H2 2017 113
  • Psoriasis - Pipeline by HitGen LTD, H2 2017 114
  • Psoriasis - Pipeline by Huabo Biopharm Co Ltd, H2 2017 114
  • Psoriasis - Pipeline by Hydra Biosciences Inc, H2 2017 114
  • Psoriasis - Pipeline by iCo Therapeutics Inc., H2 2017 115
  • Psoriasis - Pipeline by Immune Pharmaceuticals Inc, H2 2017 115
  • Psoriasis - Pipeline by Immune Response BioPharma Inc, H2 2017 116
  • Psoriasis - Pipeline by Immungenetics AG, H2 2017 116
  • Psoriasis - Pipeline by Immunwork Inc, H2 2017 116
  • Psoriasis - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 117
  • Psoriasis - Pipeline by Istesso Ltd, H2 2017 117
  • Psoriasis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 118
  • Psoriasis - Pipeline by Johnson & Johnson, H2 2017 118
  • Psoriasis - Pipeline by Just Biotherapeutics Inc, H2 2017 119
  • Psoriasis - Pipeline by Kadmon Corp LLC, H2 2017 119
  • Psoriasis - Pipeline by Kang Stem Biotech Co Ltd, H2 2017 119
  • Psoriasis - Pipeline by KPI Therapeutics Inc, H2 2017 120
  • Psoriasis - Pipeline by Kymab Ltd, H2 2017 120
  • Psoriasis - Pipeline by Lead Pharma Holding BV, H2 2017 121
  • Psoriasis - Pipeline by LEO Pharma A/S, H2 2017 121
  • Psoriasis - Pipeline by Lupin Ltd, H2 2017 122
  • Psoriasis - Pipeline by Lycera Corp, H2 2017 122
  • Psoriasis - Pipeline by mAbxience SA, H2 2017 122
  • Psoriasis - Pipeline by Maruho Co Ltd, H2 2017 123
  • Psoriasis - Pipeline by Medestea Research & Production SpA, H2 2017 123
  • Psoriasis - Pipeline by MediGene AG, H2 2017 124
  • Psoriasis - Pipeline by Merck KGaA, H2 2017 124
  • Psoriasis - Pipeline by MetrioPharm AG, H2 2017 124
  • Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 125
  • Psoriasis - Pipeline by Momenta Pharmaceuticals Inc, H2 2017 125
  • Psoriasis - Pipeline by Mycenax Biotech Inc, H2 2017 126
  • Psoriasis - Pipeline by Nimbus Therapeutics LLC, H2 2017 126
  • Psoriasis - Pipeline by NovaLead Pharma Pvt Ltd, H2 2017 127
  • Psoriasis - Pipeline by Novan Inc, H2 2017 127
  • Psoriasis - Pipeline by Novartis AG, H2 2017 128
  • Psoriasis - Pipeline by Nuevolution AB, H2 2017 128
  • Psoriasis - Pipeline by Numab Innovation AG, H2 2017 129
  • Psoriasis - Pipeline by Oncobiologics Inc, H2 2017 129
  • Psoriasis - Pipeline by Orphagen Pharmaceuticals Inc, H2 2017 129
  • Psoriasis - Pipeline by Panacea Biotec Ltd, H2 2017 130
  • Psoriasis - Pipeline by Pfizer Inc, H2 2017 130
  • Psoriasis - Pipeline by Pharis Biotec GmbH, H2 2017 131
  • Psoriasis - Pipeline by Pharmedartis GmbH, H2 2017 131
  • Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H2 2017 132
  • Psoriasis - Pipeline by Philogen SpA, H2 2017 132
  • Psoriasis - Pipeline by PinCell srl, H2 2017 132
  • Psoriasis - Pipeline by Principia Biopharma Inc, H2 2017 133
  • Psoriasis - Pipeline by Promius Pharma LLC, H2 2017 133
  • Psoriasis - Pipeline by Protalix BioTherapeutics Inc, H2 2017 133
  • Psoriasis - Pipeline by Prothena Corp Plc, H2 2017 134
  • Psoriasis - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 134
  • Psoriasis - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2017 135
  • Psoriasis - Pipeline by RedHill Biopharma Ltd, H2 2017 135
  • Psoriasis - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017 136
  • Psoriasis - Pipeline by Rigel Pharmaceuticals Inc, H2 2017 136
  • Psoriasis - Pipeline by Samumed LLC, H2 2017 137
  • Psoriasis - Pipeline by Sandoz International GmbH, H2 2017 137
  • Psoriasis - Pipeline by Sareum Holdings Plc, H2 2017 137
  • Psoriasis - Pipeline by SBI Biotech Co Ltd, H2 2017 138
  • Psoriasis - Pipeline by Shulov Innovative Science Ltd, H2 2017 138
  • Psoriasis - Pipeline by Sienna Biopharmaceuticals Inc, H2 2017 139
  • Psoriasis - Pipeline by Sigmoid Pharma Ltd, H2 2017 139
  • Psoriasis - Pipeline by Soligenix Inc, H2 2017 140
  • Psoriasis - Pipeline by Spherium Biomed SL, H2 2017 140
  • Psoriasis - Pipeline by Stemline Therapeutics Inc, H2 2017 140
  • Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2017 141
  • Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 141
  • Psoriasis - Pipeline by Switch Biotech LLC, H2 2017 142
  • Psoriasis - Pipeline by Syntrix Biosystems Inc, H2 2017 142
  • Psoriasis - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 143
  • Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 143
  • Psoriasis - Pipeline by TheraMAB LLC, H2 2017 143
  • Psoriasis - Pipeline by Tolero Pharmaceuticals Inc, H2 2017 144
  • Psoriasis - Pipeline by UCB SA, H2 2017 144
  • Psoriasis - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 145
  • Psoriasis - Pipeline by Vicore Pharma AB, H2 2017 145
  • Psoriasis - Pipeline by vTv Therapeutics Inc, H2 2017 146
  • Psoriasis - Pipeline by Wellstat Therapeutics Corp, H2 2017 146
  • Psoriasis - Pipeline by XBiotech Inc, H2 2017 147
  • Psoriasis - Pipeline by Yuhan Corp, H2 2017 147
  • Psoriasis - Dormant Projects, H2 2017 641
  • Psoriasis - Dormant Projects, H2 2017 (Contd..1), H2 2017 642
  • Psoriasis - Dormant Projects, H2 2017 (Contd..2), H2 2017 643
  • Psoriasis - Dormant Projects, H2 2017 (Contd..3), H2 2017 644
  • Psoriasis - Dormant Projects, H2 2017 (Contd..4), H2 2017 645
  • Psoriasis - Dormant Projects, H2 2017 (Contd..5), H2 2017 646
  • Psoriasis - Dormant Projects, H2 2017 (Contd..6), H2 2017 647
  • Psoriasis - Dormant Projects, H2 2017 (Contd..7), H2 2017 648
  • Psoriasis - Dormant Projects, H2 2017 (Contd..8), H2 2017 649
  • Psoriasis - Dormant Projects, H2 2017 (Contd..9), H2 2017 650
  • Psoriasis - Dormant Projects, H2 2017 (Contd..10), H2 2017 651
  • Psoriasis - Dormant Projects, H2 2017 (Contd..11), H2 2017 652
  • Psoriasis - Dormant Projects, H2 2017 (Contd..12), H2 2017 653
  • Psoriasis - Dormant Projects, H2 2017 (Contd..13), H2 2017 654
  • Psoriasis - Dormant Projects, H2 2017 (Contd..14), H2 2017 655
  • Psoriasis - Dormant Projects, H2 2017 (Contd..15), H2 2017 656
  • Psoriasis - Discontinued Products, H2 2017 657
  • Psoriasis - Discontinued Products, H2 2017 (Contd..1), H2 2017 658
  • Psoriasis - Discontinued Products, H2 2017 (Contd..2), H2 2017 659

List of Figures

  • Number of Products under Development for Psoriasis, H2 2017 38
  • Number of Products under Development by Companies, H2 2017 39
  • Number of Products under Development by Universities/Institutes, H2 2017 51
  • Number of Products by Top 10 Targets, H2 2017 69
  • Number of Products by Stage and Top 10 Targets, H2 2017 69
  • Number of Products by Top 10 Mechanism of Actions, H2 2017 75
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 75
  • Number of Products by Routes of Administration, H2 2017 81
  • Number of Products by Stage and Routes of Administration, H2 2017 81
  • Number of Products by Top 10 Molecule Types, H2 2017 83
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017 83
Back to Top